Alzheimer’s Early Detection Act of 2026 mandates coverage of Alzheimer’s biomarker testing under group health plans, individual health insurance, and.

The Alzheimer’s Early Detection Act of 2026 requires coverage of Alzheimer’s biomarker testing under group health plans, group and individual health insurance, and the Medicaid program. The Act defines biomarker testing as the analysis of an individual’s tissue, blood, or other biospecimen for the presence of a biomarker, including single-analyte tests, multiplex panel tests, protein expression, and whole genome, whole exome, and whole transcriptome sequencing.

Alzheimer’s Early Detection Act of 2026 mandates coverage of Alzheimer’s biomarker testing under group health plans, individual health insurance, and.

The Alzheimer’s Early Detection Act of 2026 requires coverage of Alzheimer’s biomarker testing under group health plans, group and individual health insurance, and the Medicaid program. The Act defines biomarker testing as the analysis of an individual’s tissue, blood, or other biospecimen for the presence of a biomarker, including single-analyte tests, multiplex panel tests, protein expression, and whole genome, whole exome, and whole transcriptome sequencing.